☆ 4.8 Letter

Sodium Zirconium Cyclosilicate for Urgent Therapy of Severe Hyperkalemia

NEW ENGLAND JOURNAL OF MEDICINE (2015)

期刊

NEW ENGLAND JOURNAL OF MEDICINE

卷 372, 期 16, 页码 1577-1578

出版社

MASSACHUSETTS MEDICAL SOC

DOI: 10.1056/NEJMc1500353

关键词

-

类别

Medicine, General & Internal

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Emergency Medicine

Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department

Shannon Hasara, Jesse Dubey, John Amatea, Nancy Finnigan

Summary: This study aimed to evaluate the efficacy and safety of SPS and SZC in lowering serum potassium levels in patients presenting to the ED with hyperkalemia. It was a retrospective cohort study conducted at a single-site ED, and the primary outcome was the change in serum potassium following SPS or SZC administration. The results showed that both SPS and SZC resulted in similar reductions in serum potassium levels.

AMERICAN JOURNAL OF EMERGENCY MEDICINE (2023)

添加到收藏夹

Article Urology & Nephrology

Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study

Wakana Kimura, Shun Minatoguchi, Tomohiro Mizuno, Shigehisa Koide, Hiroki Hayashi, Midori Hasegawa, Daijo Inaguma, Naotake Tsuboi

Summary: This study aimed to compare the effect of sodium zirconium cyclosilicate and existing potassium binders on the continuity of RAAS inhibitors in patients with hyperkalemia. The results showed that administering sodium zirconium cyclosilicate to patients with hyperkalemia can increase the use of ACEI/ARB compared to calcium polystyrene sulfonate. This suggests potential benefits of sodium zirconium cyclosilicate for patients with chronic kidney disease receiving RAAS inhibitors.

JOURNAL OF NEPHROLOGY (2023)

添加到收藏夹

Article Urology & Nephrology

Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study

Mats Nagard, Bhupinder Singh, David W. Boulton

Summary: The study suggests that sodium zirconium cyclosilicate can effectively reduce serum potassium concentration and urinary potassium excretion, with no significant impact on urinary sodium excretion, and is well tolerated.

CLINICAL KIDNEY JOURNAL (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Effects of different potassium-lowering regimens on acute hyperkalemia in hemodialysis patients: a real-world, retrospective study

Lan Yao, Xiaoyang Xing, Yubao Li, Fangxing Zhang, Ping Li, Xianhui Liang, Pei Wang

Summary: This study evaluated the efficacy and safety of potassium-lowering regimens for acute hyperkalemia in maintenance hemodialysis patients. Results showed that the IG + SZC group had the largest decrease in serum potassium levels at 2 hours, while the SPS group had the smallest decrease. SZC showed similar efficacy to IG intravenous administration in lowering potassium at 2 hours.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients

Zhaohui Ni, Renhua Lu, Xudong Xu, Xueyan Bian, Zhihong Zhou, Junwei Yang, Qun Luo, Menghua Chen, Chaosheng Chen, Xiuli Sun, Lei Yu, Qiang He, Hong Jiang, Weijie Yuan, Yi Li, Rong Zhou, Jianqin Wang, Xinzhou Zhang, Li Zuo, Xiangwen Meng, Zhiren Chang, June Zhao, Peter Wessman, DIALIZE China Study Grp

Summary: The DIALIZE China study evaluated the effectiveness of Sodium Zirconium Cyclosilicate (SZC) for the management of hyperkalemia in Chinese patients undergoing hemodialysis. The study found that SZC treatment resulted in a significantly higher proportion of responders and improved maintenance of normal serum potassium levels compared to placebo. SZC treatment was safe and effective in Chinese patients with kidney failure receiving hemodialysis.

CLINICAL THERAPEUTICS (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients

Lei Tian, Shihui Fu, Mengyuan Li, Xinrui Zhao, Hongchao Li

Summary: This study evaluated the cost-effectiveness of SZC compared to usual care in the treatment of hyperkalemia among CKD patients or HF patients in China. The results showed that SZC is a cost-effective treatment option.

FRONTIERS IN PUBLIC HEALTH (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer

Min Zhuo, Seoyoung C. Kim, Elisabetta Patorno, Julie M. Paik

Summary: This study aimed to investigate whether there is a difference in the risk of hospitalization for heart failure (HHF) between the initiation of sodium zirconium cyclosilicate (SZC) and patiromer for the treatment of hyperkalemia. The results from the matched analysis showed that the use of SZC was associated with a numerically higher risk of HHF compared to patiromer, but this difference did not reach statistical significance.

JOURNAL OF CARDIAC FAILURE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Serum potassium response to single-dose sodium zirconium cyclosilicate for the treatment of asymptomatic hyperkalemia in hospitalized patients

Haley Lewis, Benton Stamper, Alyssa Claudio Yungkurth

Summary: The study aimed to assess the efficacy of single-dose SZC compared to FDA approved TID dosing and single-dose SPS for managing asymptomatic hyperkalemia in hospitalized patients. The results showed that single-dose SZC 10 g achieved a higher proportion of patients reaching normokalemia compared to SZC 10 g x 3 doses, but lower than SPS. Therefore, single-dose SZC may be a reasonable option for managing asymptomatic hyperkalemia in the hospital setting.

PHARMACOTHERAPY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia

Alison Rydell, Corianne Thackrey, Maryam Molki, Brandon P. Mullins

Summary: This study compared the effectiveness of patiromer and sodium zirconium cyclosilicate (SZC) in patients with acute hyperkalemia. The results showed no difference between the two medications in reducing serum potassium levels, and no clinically significant differences in electrolyte changes were observed.

ANNALS OF PHARMACOTHERAPY (2023)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis

Yaru Zhang, Ruiling Xu, Fanghao Wang, Youxia Liu, Junying Xu, Na Zhao, Fajuan Cheng, Lihong Long, Junya Jia, Shan Lin

Summary: Oral sodium zirconium cyclosilicate (SZC) effectively reduces serum potassium levels in patients with hyperkalemia within 48 hours, and continued use helps in long-term potassium control, showing a favorable safety profile.

CARDIOVASCULAR DRUGS AND THERAPY (2021)

添加到收藏夹

Article Urology & Nephrology

Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE

Steven Fishbane, Martin Ford, Masafumi Fukagawa, Kieran McCafferty, Anjay Rastogi, Bruce Spinowitz, Konstantin Staroselskiy, Konstantin Vishnevskiy, Vera Lisovskaja, Ayman Al-Shurbaji, Nicolas Guzman, Sunil Bhandari

Summary: These analyses expand our knowledge of the spectrum of potassium responses with SZC in hyperkalemic hemodialysis patients, and suggest that SZC has better control over potassium gradient compared to placebo.

BMC NEPHROLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Single Dose of Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate in Hospitalized Patients With Hyperkalemia

Noah Yoo, Yong-Bum Song, Ilya Dubinsky, Jerry Altshuler

Summary: SZC is an inorganic zirconium silicate compound that selectively exchanges potassium for hydrogen and sodium. The once dose regimen of SZC was non-inferior to the once or repeated dosing regimen of SPS in reducing serum potassium levels. There were no significant differences in the rate of additional potassium-lowering therapies and the rate of normokalemia at 48 hours between the SZC and SPS groups.

ANNALS OF PHARMACOTHERAPY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

An evaluation of sodium zirconium cyclosilicate: a new treatment option for hyperkalaemia in China

Yuan Lu, Bi-Cheng Liu, Hong Liu

Summary: "The authors summarize the epidemiological features of hyperkalemia in China and review the clinical data regarding the use of sodium zirconium cyclosilicate in Chinese patients."

EXPERT OPINION ON PHARMACOTHERAPY (2023)

添加到收藏夹

Article Engineering, Biomedical

Oral sorbents for small, charged uremic toxins, and carbon block for regeneration of dialysate: fourth down and long

Stephen R. Ash

Summary: By using an oral sorbent and carbon block columns, it is possible to effectively remove uremic toxins from dialysate, simplifying the dialysis process.

ARTIFICIAL ORGANS (2023)

添加到收藏夹

Article Urology & Nephrology

Evaluation of potential drug interactions with sodium zirconium cyclosilicate: a single-center, open-label, one sequence crossover study in healthy adults

Mats Nagard, William G. Kramer, David W. Boulton

Summary: The study assessed potential pharmacokinetic interactions between sodium zirconium cyclosilicate (SZC) and nine pH-sensitive drugs, showing small changes in plasma concentration and exposure of five of the nine drugs evaluated. These PK drug interactions are consistent with transient increases in gastric pH with SZC and are unlikely to be clinically meaningful.

CLINICAL KIDNEY JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF

Jawad H. Butt, Kieran F. Docherty, Pardeep S. Jhund, Rudolf A. Boer, Michael Bohm, Akshay S. Desai, Jonathan G. Howlett, Silvio E. Inzucchi, Mikhail N. Kosiborod, Felipe A. Martinez, Jose C. Nicolau, Mark C. Petrie, Piotr Ponikowski, Olof Bengtsson, Anna Maria Langkilde, Morten Schou, Mikaela Sjostrand, Scott D. Solomon, Marc S. Sabatine, John J. McMurray, Lars Kober

Summary: In patients with HFrEF, treatment with dapagliflozin can reduce the risk of worsening HF events, cardiovascular death, and symptom improvement, regardless of the presence of AF, but has limited effectiveness in preventing new-onset AF.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

Javed Butler, Stefan D. Anker, Tariq Jamal Siddiqi, Andrew J. S. Coats, Fabio Dorigotti, Gerasimos Filippatos, Tim Friede, Udo-Michael Goehring, Mikhail N. Kosiborod, Lars H. Lund, Marco Metra, Carol Moreno Quinn, Ileana L. Pina, Fausto J. Pinto, Patrick Rossignol, Peter Szecsody, Peter Van der Meer, Matthew Weir, Bertram Pitt

Summary: The DIAMOND trial aims to assess the impact of patiromer on K+ control in patients with HFrEF and hyperkalaemia or a history of hyperkalaemia compromising RAASi therapy, to improve RAASi use.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF

Kirsty McDowell, Paul Welsh, Kieran F. Docherty, David A. Morrow, Pardeep S. Jhund, Rudolf A. de Boer, Eileen O'Meara, Silvio E. Inzucchi, Lars Kober, Mikhail N. Kosiborod, Felipe A. Martinez, Piotr Ponikowski, Ann Hammarstedt, Anna Maria Langkilde, Mikaela Sjostrand, Daniel Lindholm, Scott D. Solomon, Naveed Sattar, Marc S. Sabatine, John J. McMurray

Summary: This study examined the association between blood uric acid (UA) levels and outcomes in patients with heart failure and reduced ejection fraction (HFrEF). The results showed that higher UA levels were associated with worse outcomes. Dapagliflozin was found to reduce UA levels and improve outcomes, regardless of baseline UA concentration.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Endocrinology & Metabolism

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Yehuda Handelsman, John E. Anderson, George L. Bakris, Christie M. Ballantyne, Joshua A. Beckman, Deepak L. Bhatt, Zachary T. Bloomgarden, Biykem Bozkurt, Matthew J. Budoff, Javed Butler, Samuel Dagogo-Jack, Ian H. de Boer, Ralph A. DeFronzo, Robert H. Eckel, Daniel Einhorn, Vivian A. Fonseca, Jennifer B. Green, George Grunberger, Chris Guerin, Silvio E. Inzucchi, Paul S. Jellinger, Mikhail N. Kosiborod, Pamela Kushner, Norman Lepor, Christian W. Mende, Erin D. Michos, Jorge Plutzky, Pam R. Taub, Guillermo E. Umpierrez, Muthiah Vaduganathan, Matthew R. Weir

Summary: Type 2 diabetes, chronic kidney disease, atherosclerotic cardiovascular disease, and heart failure, along with their associated risk factors, have overlapping etiologies and frequently occur together in patients. Recent cardiovascular outcome trials have shown that drugs developed for controlling risk factors of these diseases can provide benefits in a range of conditions. Therefore, practice recommendations are needed to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and metabolic diseases.

JOURNAL OF DIABETES AND ITS COMPLICATIONS (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study

Antonio Nicolucci, Hungta Chen, Andrew Cooper, Peter Fenici, Marilia B. Gomes, Niklas Hammar, Linong Ji, Kamlesh Khunti, Mikhail Kosiborod, Jennie Medin, Marina Shestakova, Iichiro Shimomura, Fengming Tang, Jiten Vora, Hirotaka Watada, Suzanne Arnold

Summary: The DISCOVER study found that overall, health-related quality of life remained stable in patients with type 2 diabetes initiating a second-line glucose-lowering therapy. However, certain patient characteristics and the use of specific medications were associated with low or decreasing quality of life.

DIABETES RESEARCH AND CLINICAL PRACTICE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

John A. Spertus, Mary C. Birmingham, Michael Nassif, C. Damaraju, Antonio Abbate, Javed Butler, David E. Lanfear, Ildiko Lingvay, Mikhail N. Kosiborod, James L. Januzzi

Summary: Large traditional clinical trials have shown that sodium-glucose co-transporter 2 inhibitors can improve symptoms in heart failure patients. In a new trial conducted remotely (CHIEF-HF trial), canagliflozin was found to significantly improve symptoms in heart failure patients, regardless of ejection fraction or diabetes status.

NATURE MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors, Christiane E. Angermann, John R. Teerlink, Sean P. Collins, Mikhail Kosiborod, Jan Biegus, Joao Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka, Jasper Tromp, C. Jan Willem Borleffs, Changsheng Ma, Joseph Comin-Colet, Michael Fu, Stefan P. Janssens, Robert G. Kiss, Robert J. Mentz, Yasushi Sakata, Henrik Schirmer, Morten Schou, P. Christian Schulze, Lenka Spinarova, Maurizio Volterrani, Jerzy K. Wranicz, Uwe Zeymer, Shelley Zieroth, Martina Brueckmann, Jonathan P. Blatchford, Afshin Salsali, Piotr Ponikowski

Summary: The sodium-glucose cotransporter 2 inhibitor empagliflozin improves clinical outcomes in patients hospitalized for acute heart failure, regardless of ejection fraction or the presence of diabetes.

NATURE MEDICINE (2022)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease

P. Rossignol, J. Silva-Cardoso, M. N. Kosiborod, V Brandenburg, J. G. Cleland, H. Hadimeri, R. Hullin, S. Makela, D. Mortl, E. Paoletti, C. Pollock, L. Vogt, M. Jadoul, J. Butler

Summary: This article addresses the challenges of using potassium binders in patients with cardiovascular and kidney diseases, proposing two treatment algorithms to optimize their use and minimize the risks of hyperkalemia and hypokalemia.

PHARMACOLOGICAL RESEARCH (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

Kieran F. Docherty, Paul Welsh, Subodh Verma, Rudolf A. De Boer, Eileen O'Meara, Olof Bengtsson, Lars Kober, Mikhail N. Kosiborod, Ann Hammarstedt, Anna Maria Langkilde, Daniel Lindholm, Dustin J. Little, Mikaela Sjostrand, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, David A. Morrow, Morten Schou, Scott D. Solomon, Naveed Sattar, Pardeep S. Jhund, John J. McMurray

Summary: This study examined the prevalence and consequences of iron deficiency in heart failure patients and found that it was associated with worse outcomes. Dapagliflozin had an effect on markers of iron metabolism and improved outcomes regardless of iron status at baseline.

CIRCULATION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial

Alexander Peikert, Felipe A. Martinez, Muthiah Vaduganathan, Brian L. Claggett, Ian J. Kulac, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer, David DeMets, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Sanjiv J. Shah, Tzvetana Katova, Bela Merkely, Orly Vardeny, Ulrica Wilderang, Daniel Lindholm, Magnus Petersson, Anna-Maria Langkilde, John J. McMurray, Scott D. Solomon

Summary: For patients with heart failure and mildly reduced or preserved ejection fraction, dapagliflozin can reduce the risk of cardiovascular death or worsening heart failure events across different age groups, with no significant differences in safety outcomes.

CIRCULATION-HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD)

Aleesha Shaik, Mikhail Kosiborod, James A. de Lemos, Qi Gao, Katherine E. Mues, Shushama Alam, Deepak L. Bhatt, Christopher P. Cannon, Christie M. Ballantyne, Robert S. Rosenson

Summary: In patients with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), the use of statins is high but not universal, and the rates of high-intensity statin and ezetimibe use remain low.

CLINICAL CARDIOLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK

Suping Ling, Francesco Zaccardi, Bogdan Vlacho, Ping Li, Jordi Real Gatius, Manel Mata-Cases, Josep Franch-Nadal, Mikhail N. Kosiborod, Clare Gillies, Peter Fenici, Didac Mauricio, Baiju R. Shah, Kamlesh Khunti

Summary: This study aimed to understand the geographical and temporal patterns in the excess mortality risk associated with type 2 diabetes (T2D) in three high-income countries. The results showed similar diabetes gaps between Ontario and England, particularly in elderly subjects, while Catalonia had lower mortality rates in men with T2D from the age of 60 years.

DIABETES OBESITY & METABOLISM (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

Mikhail N. Kosiborod, Meena Bhatta, Melanie Davies, John E. Deanfield, W. Timothy Garvey, Usman Khalid, Robert Kushner, Domenica M. Rubino, Niels Zeuthen, Subodh Verma

Summary: This study evaluated the effects of once-weekly subcutaneous semaglutide 2.4 mg on cardiometabolic risk factors in people with overweight/obesity without diabetes. The results showed that semaglutide can improve waist circumference, blood pressure, blood glucose, and lipid levels, and reduce the use of antihypertensive and lipid-lowering medications. However, these benefits were not maintained after treatment discontinuation.

DIABETES OBESITY & METABOLISM (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

Jan Biegus, Adriaan A. Voors, Sean P. Collins, Mikhail N. Kosiborod, John R. Teerlink, Christiane E. Angermann, Jasper Tromp, Joao Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka, Martina Brueckmann, Afshin Salsali, Jonathan P. Blatchford, Piotr Ponikowski

Summary: This study evaluated the decongestion effects of empagliflozin in patients with acute heart failure (AHF) and found that compared to placebo, empagliflozin significantly reduced markers of decongestion at all time-points. Patients with greater weight loss within the first 15 days showed higher clinical benefit at Day 90.

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Prespecified Analysis of the DELIVER Randomized Clinical Trial

Finnian R. Mc Causland, Brian L. Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep Jhund, Rudolf A. de Boer, Kieran Docherty, James Fang, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe Martinez, Jose F. Kerr Saraiva, Martina M. McGrath, Sanjiv J. Shah, Subodh Verma, Anna Maria Langkilde, Magnus Petersson, John J. McMurray, Scott D. Solomon

Summary: Dapagliflozin has no effect on baseline kidney function in patients with heart failure and a mildly reduced or preserved ejection fraction. Dapagliflozin does not significantly reduce the frequency of kidney composite outcomes, but can slow the decline in eGFR.

JAMA CARDIOLOGY (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.